The latest lung cancer news from reliable sources can be found on the Medi-Paper website. Get an instant update with the latest developments in lung cancer.

Kris on the Success of Durvalumab as a Major Advancement in NSCLC

In an interview with Targeted Oncology, Kris, a medical oncologist and the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, discussed how the approval of durvalumab has changed the treatment landscape of NSCLC.

Read full article (External website)

Death due to cancer on the decline for most tumours in Europe

The exceptions are death due to lung and pancreatic carcinoma in women which are both still on the rise, according to a new study, published in Annals of Oncology on the 19th of March 2018.

Researchers predict that the death rates for most types of cancer will be lower in 2018 when compared to 2012 in the European Union.

The study, led by Carlo La Vecchia (MD) of the University of Milan, shows that death due to colorectal cancer (CRC) is on the decline in Europe. The researchers call the drop in death-rates of CRC, which is the most common cause of cancer-death in non-smoking males and females, one of the major achievements in the management of oncologic diseases over the recent years.

Key numbers for CRC:

  • CRC is the second highest cause of cancer-death: 177,400 (male: 98,000 in men; female 79,400);
  • Due to the ageing population, the absolute quantities of fatalities have risen since 2012;
  • In contrast, the age-standardised rates will decrease by 6.7% in men (15.8 per 100,000) and 7.5% in women (9.2 per 100,000).

Risk factors for CRC include:

  • Tobacco
  • Alcohol
  • Obesity
  • Diabetes
  • Sedentary lifestyle
  • Unhealthy diet

The use of oral contraceptives and hormone-replacement therapy in women may partly explain the decreased risk in females. Furthermore, the use of aspirin for prevention of cardiovascular disease and effective screening may further contribute to a decrease in the incidence of the disease in both sexes.

Key numbers for all cancers in Europe:

  • In 2018, 1.4 million cancer deaths are predicted, up from 1.3 million in 2012.
  • Death-rates have fallen by 10.3% in men and 5% in women
  • Age-standardised death rates in 2018 are predicted to be 130 per 100,000 for men and 84 per 100,000 for women.


  1. Malvezzi M et al. Ann Oncol. doi:10.1093/annonc/mdy033

Surgical Techniques Continue to Evolve in NSCLC

Jason M. Long, MD, discusses the latest developments with minimally invasive surgical approaches in the treatment of patients with non–small cell lung cancer (NSCLC).

Read full article (External website)

Weiss Weighs In on Challenges in NSCLC

Jared Weiss, MD, shares his insight on challenges in the field of non–small cell lung cancer, such as optimal sequencing.

Read full article (External website)

ELCC 2018 Media Alert: Fighting Number-one Cancer Killer With Research and A Multidisciplinary Approach

Around 2,300 participants from across the world will meet in Geneva at the eighth European Lung Cancer Congress (ELCC 2018, 11-14 April 2018) to learn about and discuss the latest research in the field of lung cancer.

Read full article (External website)

EMA Suggests Extension of Therapeutic Indications for Denosumab

Extension of indication includes the avoidance of skeletal-related events in grown-ups with late-stage malignancies involving the bone

On 22 February 2018, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending towards a change in the marketing authorisation for denosumab (licensee: Amgen Europe BV).

The following extension of the label was adopted by the CHMP:

  • Prevention of skeletal-related events in adults with advanced malignancies involving bone (e.g. pathological fracture, radiation to the bone, spinal cord compression, or surgery to the bone).

Previously, denosumab was only indicated for the prevention of skeletal-related events in adults with bone metastases from solid tumours.


Expert Discusses Immunotherapy Growth in Treatment Landscape of NSCLC

The treatment landscape of non-small cell lung cancer has been identifying the importance of immunotherapy already, but combination therapies will soon play a large role in treatment of these patients as well, according to Chad Pecot, MD.

Read full article (External website)

Immune-Modified Response Criteria in Solid Tumours

Analyzis of atezolizumab data in clinical trials including NSCLC, mUC, RCC and melanoma patients may inform additional modifications to response evaluation criteria

Read full article (External website)

trial Finds Survival Benefit With Upfront Atezolizumab Combo for NSCLC

According to findings from the Phase 3 IMpower150 trial, significant improvement was found in overall survival with a treatment regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel compared to the combination of bevacizumab and chemotherapy alone for patients with advanced nonsquamous non–small cell lung cancer.

Read full article (External website)

PFS Improved in Frontline Squamous NSCLC with Atezolizumab Plus Chemo

PFS Improved in Frontline Squamous NSCLC with Atezolizumab Plus Chemo

2018-03-29 10:54:57

According to topline findings from the Phase 3 IMpower131 trial, the addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel delayed progression or death compared with chemotherapy alone for patients with advanced squamous non–small cell lung cancer. These results were released by Genentech, the manufacturer of the anti–PD-L1 agent.


ELCC 2018 Press Release: Heine H. Hansen Award Given to Fabrice Barlesi

2018-03-27 06:05:00

The European Society for Medical Oncology (ESMO) and the International Association for the trial of Lung Cancer (IASLC) have announced that the 2018 Heine H. Hansen (HHH) Award will be given to Fabrice Barlesi.


Durvalumab Success Signifies New Era in Stage III NSCLC

Durvalumab Success Signifies New Era in Stage III NSCLC

2018-03-29 02:00:00

Edward S. Kim, MD, recaps the findings from the PACIFIC trial of durvalumab and discussed the treatment of patients with stage III NSCLC.


Challenges Continue With Lung Cancer Screening

Challenges Continue With Lung Cancer Screening

2018-03-29 02:42:00

M. Patricia Rivera, MD, discusses the potential of lung cancer screening, challenges in its adoption, and methods to enhance its efficacy.